Supriya Lifescience IPO is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (“APIs”), with a focus on research and development. Supriya Lifescience IPO has niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anesthetic, vitamin, anti-asthmatic and anti-allergic.
Supriya Lifescience IPO has consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, It is among the largest exporters of Salbutamol Sulphate from India. In 2021, its products were exported to 78 countries to 1,060 customers including 286 distributors. Supriya Lifescience IPO had grown its API business in several countries across Europe, Latin America, Asia, North America & India.
Supriya Lifescience IPO customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc, and AT Planejamento E Desenvolvimento De Negocios Ltda, with whom it has a business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd, and Mankind Pharma Ltd with whom it has a business relationship for over four years.
Supriya Lifescience IPO business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. Supriya Lifescience has a team of 16 scientists. Its R&D efforts are demonstrated by a strong pipeline of products such as Dextromethorphan Hydrobromide, Pentoxifylline, (S)-Ketamine Hydrochloride, Phenylephrine Hydrochloride, Allopurinol, and Benfotiamine.
Competitive Strengths
- Significant scale with a leadership position across key & niche products
- Backward integrated business model
- Advanced manufacturing and research and development capabilities
- Consistent strong financial performance due to de-risked business model
- Experienced senior management team and qualified operational personnel
Supriya Lifescience IPO – Business Strategy
- Expansion of manufacturing capabilities
- Expanding product portfolio with increasing R&D capabilities
- Increase current market presence and enter new markets
- Continue to focus on operational excellence
Company Promoters
- Satish Waman Wagh
Company Financials
| Amount (in INR & Million) | ||||
| 31-Dec-20 | 31-Mar-20 | Mar-19 | 31-Mar-18 | |
| Total Assets | 3,568.28 | 3,364.01 | 2,530.52 | 2,453.95 |
| *Total Revenue | 2,679.27 | 3,227.13 | 2,858.62 | 2,215.10 |
| Total Expense | 1,530.69 | 2,132.62 | 2,131.01 | 1,909.60 |
| Profit After Tax | 761.86 | 733.74 | 394.24 | 87.28 |
Objects Of The Issue
- Funding capital expenditure requirements of their Company
- Funding capital expenditure requirements of their Company
- Repayment and/ or pre-payment, in full or part, of certain borrowings availed by their Company
- General corporate purposes
Supriya Lifescience IPO – Details
| IPO Opening Date | 16 December 2021 |
| IPO Closing Date | 20 December 2021 |
| Issue Type | Book Built Issue IPO |
| Issue Size | ₹700 Crore |
| Face Value | ₹2 per equity share |
| IPO Price | ₹265 To ₹274 Per Equity Share |
| Market Lot | 54 Shares (1 Lot) |
| Min Order | 54 Shares |
| Listing At | BSE, NSE |
| Register | LinkInTime India Private Ltd |
Supriya Lifescience IPO – Date Schedule
| IPO Open Date | 16 December 2021 |
| IPO Close Date | 20 December 2021 |
| Basis of Allotment Date | 23 December 2021 |
| Initiation of Refunds | 24 December 2021 |
| Credit of Shares to Demat Account | 27 December 2021 |
| IPO Listing Date | 28 December 2021 |
Supriya Lifescience IPO – Lots Size & Price
| Application | Lots | Shares | Amount ( Cut-Off) |
| Minimum | 1 | 54 | 14,796 |
| Maximum | 13 | 702 | 1,92,348 |
Promoter Holding
| Pre Issue Share Holding | 99.98% |
| Post Issue Share Holding |
Supriya Lifescience IPO Prospectus
Company Contact Information
| Supriya Lifescience Limited 207/208, Udyog Bhavan, Sonawala Road, Goregaon – East, Mumbai – 400063, Maharashtra, India; Phone: +91-22-40332727 Email: cs@supriyalifescience.com Website: https://www.supriyalifescience.com/ |
Supriya Lifescience IPO Registrar
| Link Intime India Private Limited C-101, 1st Floor, 247 Park Lal Bahadur Shastri Marg Vikhroli (West) Mumbai 400 083 Maharashtra, India Tel: +91 22 4918 6200 E-mail: supriyalife.ipo@linkintine.co.in Website: : : www.linkintime.co.in |
Supriya Lifescience IPO Lead Manager(s)
| 1. ICICI Securities Limited 2. Axis Capital Limited |
Supriya Lifescience IPO FAQs
| When Supriya Lifescience IPO will open? The Supriya Lifescience IPO dates are 16 December 2021 To 20 December 2021. |
| What is the lot size of Supriya Lifescience IPO? Supriya Lifescience IPO lot size is 54 Shares and total amount is ₹14,796. |
| How to apply for Supriya Lifescience IPO? You can apply in Supriya Lifescience IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don’t offer banking services. |
| When is Supriya Lifescience IPO listing date? The Supriya Lifescience IPO listing date is announced. The date of Supriya Lifescience IPO listing is 28 December 2021. |
